Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response-Reference-Cited by-同舟云学术

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Published:2020-10-19 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

De Souza Andre,Tavora Fabio A.,Mahalingam Devalingam,Munster Pamela N.,Safran Howard P.,El-Deiry Wafik S.,Carneiro Benedito A.

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference18 articles.

1. GSK-3 inhibition as a therapeutic approach against SARs CoV2: dual benefit of inhibiting viral replication while potentiating the immune response;Rudd;Front Immunol.,2020

2. Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses;Taylor;Immunity.,2016

3. Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy;Taylor;Cancer Res.,2018

4. Inhibition of glycogen synthase kinase (GSK)-3-beta improves liver microcirculation and hepatocellular function after hemorrhagic shock;Jellestad;Eur J Pharmacol.,2014

5. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat;Dugo;Crit Care Med.,2005

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enzymes in the time of COVID‐19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs;Medicinal Research Reviews;2022-06-28

2. Impact of SARS-CoV-2 on Host Factors Involved in Mental Disorders;Frontiers in Microbiology;2022-04-04

3. Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy;Journal of Medicinal Chemistry;2021-06-03